reta ghk-cu mt2 Peptide GHK-CU – Australian Peptide Clinic

They'll serve different niches: CagriSema Will Dominate: Patients familiar with Wegovy brand Those wanting proven semaglutide component People with type 2 diabetes (strong REIMAGINE data) Earlier availability (mid-2027) Retatrutide Will Dominate: Patients needing maximum weight loss (BMI 40) Those with multiple complications (OA + OSA + obesity) People who failed CagriSema Willingness to wait for highest efficacy Tirzepatide (Zepbound) Will Remain Relevant: Already available NOW Proven safety with 22.5% weight loss Lower cost than either new option Established insurance coverage The High-Dose CagriSema Wildcard Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026tripling the cagrilintide dose

For patients on established B12 injection therapy, monitoring is based primarily on clinical response and haematological parameters rather than routine serum B12 measurements, which may remain very high without indicating harm or overtreatment

The peptide is not stored or sequestered long-term

Safety and Compliance Regulatory authorities classify BPC-157 as a research-only compound and have not approved it as a drug, supplement, or therapeutic agent

Ehses JA, Pelech SL, Pederson RA, et al

Medically reviewed by Alan Lucks | MD , Alan Lucks MDPC Private Practice - New York on July 12th, 2025